Good Morning All,
Remember the old saying - nothing is created in a vacuum?
Even though the markets are forward looking - it behooves us to look at the past so that we may understand the future.
Below is a excerpt from SOBM's 8K-3/1/07. It's an excellent read and the full article can be found at:
http://www.secinfo.com/d12TC3.uBu2.d.htm
"Sinobiomed Inc. is the sole shareholder of Wanxin Bio-Technology Limited, a BVI company which is the sole shareholder of Manhing Enterprises Limited, a Hong Kong company, and Manhing Enterprises Limited is the registered owner of 82% of the capital of Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. In addition, Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. is the registered owner of 50.33% of the capital of Shanghai Wanxing Bio-science Cosmetic Co., Ltd.
Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. ("Shanghai Wanxing") is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Shanghai Wanxing currently has 10 products approved or in development: two on the market, one awaiting approval, four in clinical trials and three in research and development. Shanghai Wanxing's products respond to a wide range of diseases and conditions, including malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration.
Shanghai Wanxing has proven expertise in recombinant protein drug development. This category of drugs - developed using biotechnology -- are valued for their safety, lower cost of production and efficacy compared to chemical drugs. These biopharmaceuticals are becoming one of the fastest growing segments in the global pharmaceutical industry.
Shanghai Wanxing also has proven expertise in recombinant protein manufacturing technology and a patented low-cost, high-yield production process to enhance bioactivity and guarantee the highest levels or purity. It also has one of China's largest capacities for the manufacture of recombinant bio-products. Shanghai Wanxing also has strong strategic alliances with leading Chinese research hospitals and institutes for collaborative development of patented and patentable techniques and treatments. This domestic strength is complemented by established relationships with internationally recognized health researchers and organizations."
Please note the following:
Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. (“Shanghai Wanxing”) specializes in the development of genetically engineered recombinant protein drugs and vaccines, and currently has 10 products approved or in development, which respond to a wide range of diseases, including malaria and hepatitis. The development of Shanghai Wanxing’s malaria vaccine candidate is supported by the World Health Organization (WHO) and the Program for appropriate Technology in Health’s (PATH) Malaria Vaccine Initiative (MVI), which to date has received more than $250 million in funding from the Bill and Melinda Gates Foundation. Malaria threatens some two billion people and kills and estimated one million annually worldwide; there is currently no vaccine. Shanghai Wanxing’s candidate vaccine received a US patent in September 2006.
I've added a link which is May 2008 on Phase ll Trials of SOBM's Malaria Vaccine.
Phase ll Trials in the US usually take 2 years to complete. However these trials are being done by Mahidol University in Bangkok, Thailand and I'm not sure how long they take. Also if you can not access info by this link - go to redorbit.com - click on news - then health- and type in Sinobiomed.
http://www.redorbit.com/news/health/1385194/phase_ii_clinical_trial_of_sinobiomeds_malaria_candidate_vaccine_to/index.html
And finally, I've listed the link for Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. which shows - amoung other things - a list of drugs in the pipeline and much more
http://www.wanxing-bio.com.cn/en/science/science.asp?cata=3&subcata=5
Please understand that the following is solely my opinion; but
It appears to me that after a two year hiatus, SOBM's re-birth into the market is well thought out and well planned.
We all crawl before we learn to walk.
I believe that right now SOBM is now laying the ground work for it's new beginnings.
After that will come the financials.
Soon we will learn of new acquisitions and mergers.
Then, we will see how it all fits together with the results of their clinical trials.
With the success of the trials comes the saving of thousands of lives.
And just think - all of this for the bargin basement price of $0.189.
Wonder what it will be in a year.
This post is for informational purposes only and should not be construed as an offer or solicitation to buy or sell securities